|
End-of-day quote
OTC Bulletin Board
|
||
| - USD | - |
|
| 08-19 | Cellectar Biosciences, Inc. - Special Call | |
| 08-13 | Cellectar Biosciences, Inc., Q2 2026 Earnings Call, Aug 13, 2026 |
| Market Cap | 24.48M 20.96M 19.56M 17.95M 33.72M 2.34B 34.38M 232M 90.44M 1.17B 91.92M 89.92M 3.89B | P/E 2026 * |
-1.07x | P/E 2027 * | -1.35x |
|---|---|---|---|---|---|
| Enterprise Value | 24.48M 20.96M 19.56M 17.95M 33.72M 2.34B 34.38M 232M 90.44M 1.17B 91.92M 89.92M 3.89B | EV / Sales 2026 * |
-
| EV / Sales 2027 * | 3.2x |
| Free-Float |
98.25% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: NOVELOS THERAP
| Manager | Title | Age | Since |
|---|---|---|---|
James Caruso
CEO | Chief Executive Officer | 66 | 15/06/2015 |
Chad Kolean
DFI | Director of Finance/CFO | 60 | 28/05/2014 |
Jarrod Longcor
COO | Chief Operating Officer | 52 | 23/02/2022 |
| Director | Title | Age | Since |
|---|---|---|---|
John Neis
BRD | Director/Board Member | 69 | 01/02/2008 |
James Caruso
BRD | Director/Board Member | 66 | 15/06/2015 |
Douglas Swirsky
CHM | Chairman | 56 | 01/08/2017 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +2.02% | +7.28% | +78.36% | +130.17% | 1,109B | |
| +1.57% | +4.30% | +51.76% | +62.26% | 644B | |
| +1.56% | +6.66% | +27.00% | +77.19% | 463B | |
| +1.04% | +5.38% | +42.55% | +47.15% | 371B | |
| +0.95% | +4.18% | +24.01% | +41.73% | 301B | |
| +1.19% | +6.63% | +1.43% | +14.48% | 256B | |
| +1.92% | +5.78% | +48.51% | +68.48% | 234B | |
| +1.59% | +2.09% | -15.52% | -52.29% | 205B | |
| +2.59% | +6.40% | +26.76% | +93.86% | 178B | |
| Average | +1.58% | +3.00% | +31.65% | +53.67% | 417.9B | |
| Weighted average by Cap. | +1.63% | +3.26% | +44.96% | +73.39% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | - | 7.65M 6.55M 6.11M 5.61M 10.54M 732M 10.74M 72.49M 28.26M 367M 28.72M 28.09M 1.21B |
| Net income | -31.63M -27.08M -25.27M -23.19M -43.57M -3.03B -44.43M -300M -117M -1.52B -119M -116M -5.02B | -37.38M -32M -29.86M -27.4M -51.48M -3.58B -52.49M -354M -138M -1.79B -140M -137M -5.93B |
| Net Debt | - | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
- Stock Market
- Stocks
- CLRB Stock
- NVLTD Stock
Select your edition
All financial news and data tailored to specific country editions
